Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity.

Chaudhury S, Duncan EH, Atre T, Dutta S, Spring MD, Leitner WW, Bergmann-Leitner ES.

Hum Vaccin Immunother. 2019 Oct 7:1-12. doi: 10.1080/21645515.2019.1654807. [Epub ahead of print]

PMID:
31589550
2.

Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).

Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S.

Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28.

3.

Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.

Atre T, Robinson TM, Savransky T, Dutta S, Epstein JE, Bergmann-Leitner ES.

Malar J. 2019 May 29;18(1):186. doi: 10.1186/s12936-019-2819-6.

4.

Development and characterization of a Zaire Ebola (ZEBOV) specific IgM ELISA.

Atre T, Phillips RL, Modjarrad K, Regules JA, Bergmann-Leitner ES.

J Immunol Methods. 2019 May;468:29-34. doi: 10.1016/j.jim.2019.03.008. Epub 2019 Mar 22.

PMID:
30910536
5.

The Selection of a Hepatocyte Cell Line Susceptible to Plasmodium falciparum Sporozoite Invasion That Is Associated With Expression of Glypican-3.

Tweedell RE, Tao D, Hamerly T, Robinson TM, Larsen S, Grønning AGB, Norris AM, King JG, Law HCH, Baumbach J, Bergmann-Leitner ES, Dinglasan RR.

Front Microbiol. 2019 Feb 28;10:127. doi: 10.3389/fmicb.2019.00127. eCollection 2019.

6.

Correlation Between Malaria-Specific Antibody Profiles and Responses to Artemisinin Combination Therapy for Treatment of Uncomplicated Malaria in Western Kenya.

Odhiambo G, Bergmann-Leitner E, Maraka M, Wanjala CNL, Duncan E, Waitumbi J, Andagalu B, Jura WGZO, Dutta S, Angov E, Ogutu BR, Kamau E, Ochiel D.

J Infect Dis. 2019 May 24;219(12):1969-1979. doi: 10.1093/infdis/jiz027.

PMID:
30649381
7.

Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Hall CE, Hagan LM, Bergmann-Leitner E, Tosh DM, Bennett JW, Regules JA, Chuang I, Angov E, Dutta S, Chattopadhyay D, Yadava A.

Infect Immun. 2019 Feb 21;87(3). pii: e00541-18. doi: 10.1128/IAI.00541-18. Print 2019 Mar.

8.

Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning.

Chaudhury S, Duncan EH, Atre T, Storme CK, Beck K, Kaba SA, Lanar DE, Bergmann-Leitner ES.

Sci Rep. 2018 Nov 30;8(1):17508. doi: 10.1038/s41598-018-35452-x.

9.

Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine.

Kaba SA, Karch CP, Seth L, Ferlez KMB, Storme CK, Pesavento DM, Laughlin PY, Bergmann-Leitner ES, Burkhard P, Lanar DE.

Vaccine. 2018 Feb 1;36(6):906-914. doi: 10.1016/j.vaccine.2017.12.001. Epub 2017 Dec 29.

10.

Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity.

Knepper TA, Duncan EH, Savransky T, Bergmann-Leitner ES.

Malar J. 2017 Nov 29;16(1):484. doi: 10.1186/s12936-017-2129-9.

11.

Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis.

Chaudhury S, Regules JA, Darko CA, Dutta S, Wallqvist A, Waters NC, Jongert E, Lemiale F, Bergmann-Leitner ES.

Sci Rep. 2017 Aug 11;7(1):7998. doi: 10.1038/s41598-017-08526-5.

12.

Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S.

Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7.

13.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.

Laurens MB, Kouriba B, Bergmann-Leitner E, Angov E, Coulibaly D, Diarra I, Daou M, Niangaly A, Blackwelder WC, Wu Y, Cohen J, Ballou WR, Vekemans J, Lanar DE, Dutta S, Diggs C, Soisson L, Heppner DG, Doumbo OK, Plowe CV, Thera MA.

PLoS One. 2017 Mar 10;12(3):e0173294. doi: 10.1371/journal.pone.0173294. eCollection 2017.

14.

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.

Farooq F, Beck K, Paolino KM, Phillips R, Waters NC, Regules JA, Bergmann-Leitner ES.

Sci Rep. 2016 Jun 21;6:27944. doi: 10.1038/srep27944.

15.

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.

Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC, Lemiale F, Bergmann-Leitner E.

Malar J. 2016 May 31;15:301. doi: 10.1186/s12936-016-1348-9.

16.

Vaccination Using Gene-Gun Technology.

Bergmann-Leitner ES, Leitner WW.

Methods Mol Biol. 2015;1325:289-302. doi: 10.1007/978-1-4939-2815-6_22.

PMID:
26450396
17.

Miniaturized Growth Inhibition Assay to Assess the Anti-blood Stage Activity of Antibodies.

Duncan EH, Bergmann-Leitner ES.

Methods Mol Biol. 2015;1325:153-65. doi: 10.1007/978-1-4939-2815-6_13.

PMID:
26450387
18.

Immune Escape Mechanisms are Plasmodium's Secret Weapons Foiling the Success of Potent and Persistently Efficacious Malaria Vaccines.

Farooq F, Bergmann-Leitner ES.

Clin Immunol. 2015 Dec;161(2):136-43. doi: 10.1016/j.clim.2015.08.015. Epub 2015 Sep 3. Review.

PMID:
26342537
19.

Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Bergmann-Leitner ES, Leitner WW.

Vaccines (Basel). 2014 Apr 10;2(2):252-96. doi: 10.3390/vaccines2020252. Review.

20.

Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen.

Bergmann-Leitner ES, Chaudhury S, Steers NJ, Sabato M, Delvecchio V, Wallqvist AS, Ockenhouse CF, Angov E.

PLoS One. 2013 Aug 16;8(8):e71610. doi: 10.1371/journal.pone.0071610. eCollection 2013.

21.

Improving DNA vaccines against malaria: could immunization by gene gun be the answer?

Bergmann-Leitner ES, Leitner WW.

Ther Deliv. 2013 Jul;4(7):767-70. doi: 10.4155/tde.13.48. No abstract available.

PMID:
23883119
22.

Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria.

Bergmann-Leitner ES, Hosie H, Trichilo J, Deriso E, Ranallo RT, Alefantis T, Savranskaya T, Grewal P, Ockenhouse CF, Venkatesan MM, Delvecchio VG, Angov E.

Front Immunol. 2013 Jul 4;4:176. doi: 10.3389/fimmu.2013.00176. eCollection 2013.

23.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14.

24.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD.

Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.

25.

Gene gun immunization to combat malaria.

Bergmann-Leitner ES, Leitner WW.

Methods Mol Biol. 2013;940:269-84. doi: 10.1007/978-1-62703-110-3_21.

PMID:
23104349
26.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

27.

Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice.

Khan F, Legler PM, Mease RM, Duncan EH, Bergmann-Leitner ES, Angov E.

Biotechnol J. 2012 Jan;7(1):133-47. doi: 10.1002/biot.201100331. Epub 2011 Dec 28.

PMID:
22076863
28.

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E.

Vaccine. 2011 Aug 11;29(35):5940-9. doi: 10.1016/j.vaccine.2011.06.053. Epub 2011 Jun 29.

PMID:
21722682
29.

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ.

J Infect Dis. 2011 Jul 1;204(1):9-18. doi: 10.1093/infdis/jir222.

30.

Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei.

Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E.

PLoS One. 2010 Aug 19;5(8):e12294. doi: 10.1371/journal.pone.0012294.

31.
32.

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.

PMID:
19857448
33.

MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum.

Bergmann-Leitner ES, Duncan EH, Angov E.

Malar J. 2009 Aug 3;8:183. doi: 10.1186/1475-2875-8-183.

34.

Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.

Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ.

Cancer Sci. 2009 Sep;100(9):1748-56. doi: 10.1111/j.1349-7006.2009.01244.x. Epub 2009 Jun 17.

35.

Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.

Bergmann-Leitner ES, Leitner WW, Duncan EH, Savranskaya T, Angov E.

Vaccine. 2009 Sep 18;27(41):5700-8. doi: 10.1016/j.vaccine.2009.06.059. Epub 2009 Jul 2.

PMID:
19576940
36.

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr.

PLoS One. 2009;4(4):e5254. doi: 10.1371/journal.pone.0005254. Epub 2009 Apr 23.

37.

Anti-cancer drugs.

Bergmann-Leitner E.

Curr Pharm Des. 2009;15(7):730-1. No abstract available.

PMID:
19275638
38.

Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults.

Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, Sumba PO, Beeson JG, Angov E, Moormann AM, Kazura JW.

PLoS One. 2008;3(10):e3557. doi: 10.1371/journal.pone.0003557. Epub 2008 Oct 29.

39.

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.

PLoS One. 2008 Jul 30;3(7):e2830. doi: 10.1371/journal.pone.0002830.

40.

Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies.

Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E.

Malar J. 2008 Jul 14;7:129. doi: 10.1186/1475-2875-7-129.

41.

Anti-cancer drugs.

Bergmann-Leitner E.

Curr Pharm Des. 2008;14(11):1048. No abstract available.

PMID:
18473853
42.
43.

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV.

PLoS One. 2008 Jan 23;3(1):e1465. doi: 10.1371/journal.pone.0001465.

44.

C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.

Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC.

Vaccine. 2007 Nov 7;25(45):7732-6. Epub 2007 Sep 4.

PMID:
17931754
45.

MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis.

Neutzner M, Lopez T, Feng X, Bergmann-Leitner ES, Leitner WW, Udey MC.

Cancer Res. 2007 Jul 15;67(14):6777-85.

46.

Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.

Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA, Angov E, Lyon JA.

Am J Trop Med Hyg. 2006 Sep;75(3):437-42.

PMID:
16968918
47.

Complement 3d: from molecular adjuvant to target of immune escape mechanisms.

Bergmann-Leitner ES, Leitner WW, Tsokos GC.

Clin Immunol. 2006 Nov;121(2):177-85. Epub 2006 Aug 17. Review.

PMID:
16914381
48.

Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP.

Vaccine. 2006 Jun 12;24(24):5110-8. Epub 2006 May 6.

49.

Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids.

Molnár J, Gyémánt N, Tanaka M, Hohmann J, Bergmann-Leitner E, Molnár P, Deli J, Didiziapetris R, Ferreira MJ.

Curr Pharm Des. 2006;12(3):287-311. Review.

PMID:
16454745
50.

C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.

Bergmann-Leitner ES, Scheiblhofer S, Weiss R, Duncan EH, Leitner WW, Chen D, Angov E, Khan F, Williams JL, Winter DB, Thalhamer J, Lyon JA, Tsokos GC.

Int Immunol. 2005 Mar;17(3):245-55. Epub 2005 Feb 14.

PMID:
15710912

Supplemental Content

Loading ...
Support Center